What's New?
HemoGenix® launches the largest role-out of new assays in its 11 year history.
1/1/2012. HemoGenix has launched the largest nummber of new assays in its history. These include the fluorescence and absorbance assay HemoFLUOR™-96 and HemoLIGHT™-96 for hematopoietic stem and progenitor cells that join the HALO® and CAMEO™ assay platforms. In addition, HemoFLUOR™-96 PCAEQ and HemoLIGHT™-96 PCAEQ now joins HALO®-96 PCAEQ as CFU/CFC equivalent assays for hematopoietic cellular therapy. HALO®-96 PMT is joined by HemoFLUOR™-96 PMT and HemoLIGHT™-96 PMT as engraftment and reconstitution assays.
The ATP bioluminescence LUMENESC™-96 assays are accompanied by MSCFluor™-96 and MSCLight™-96 fluorescence and absorbance assays, respectively for mesenchymal stem/stromal cells.
New to the HemoGenix® product line are assays for immune cells, including the lymphocyte proliferation assays, Immuno-Glo™-96, ImmunoFLUOR™-96 and ImmunoLIGHT™-96 and mixed lymphocyte culture assays, ImmunoGlo™-MLC.
Go to the Products pull-down menu for more information on these new assays.
HemoGenix® Press Release for White Paper on Stem Cell Toxicity Testing
11/18/2011. A Press Release on the recently published White Paper entitled "Stem Cells and Predictive In Vitro Toxicity Testing" was released today. To read the Press Release, please click here.
HemoGenix® publishes a New White Paper on Stem Cell Toxicity Testing
11/15/2011. HemoGenix® is a leader in stem cell toxicity testing providing both proprietary contract research services and assay kits for several different stem cell systems. Today, HemoGenix published a definitive White Paper on "Stem Cells and Predictive In Vitro Toxicity Testing". The article describes what the characteristics of stem cells and how they can be detected. The article also tackles the question of whether embryonic stem (ES) cells and induced pluripotent stem (iPS) cells can be used to predict toxicity and what should be learnt prior to this occuring. To download the White Paper, click here.
HemoGenix® launches new In Vitro Immunotoxicity Testing Service
11/15/2011. HemoGenix® launched its new contract research service for in vitro toxicity testing. Together with its extensive array of hemotoxicity screening and testing services, the inclusion of in vitro immunotoxicity testing enhances and completes the company's capability for detecting effects on the lympho-hematopoietic stem cell system. For more information on In Vitro Immunotoxicity Testing, click here.
Co-Marketing Agreement with ArunA Biomedical
4/8/2011. HemoGenix® is proud to announce a co-marketing agreement with ArunA Biomedical. ArunA was the first company to commercialize human embryonic stem (ES) cell-derived neuronal and mesenchymal stem cells (MSC). These cell lines will be used in the HemoGenix® LumiSTEM™ and LUMENESC™ contract research toxicity assay platforms, respectively, to provide the biopharmaceutical industry and environmental agencies with the ability to screen and test compound libraries for their effects on these types. Read the Press Release.
HemoGenix® Announces the Launch of LumiCYTE™-HT, a Contract Services In Vitro Hepatotoxicity Screening Platform.
3/29/2011. HemoGenix® has become the leader in hemotoxicity screening and testing using its HALO®-Tox HT bioluminomics™ platform. It has also developed two other bioluminomics™ assay platforms namely, LUMENESC™-Tox HT for mesenchymal stem cells and LumiSTEM™-Tox HT for primary stem and explanted cells, stem cell lines and transformed cell lines. A special variation of the LumiSTEM™-Tox HT platform has now been developed, called LumiCYTE™-HT, specifically for hepatotoxicity screening and testing contract services provided by HemoGenix®. To learn more about the HemoGenix® LumiCYTE™-HT contract service, please click here.
HemoGenix® Launches New Website.
3/25/2011. Information and technology surrounds us. Accessing and understanding the information and technology becomes more difficult. The new HemoGenix website focuses on scientific applications related to several biological systems and the methods by which these systems can provide information using advanced assay technology. The website has been designed so that the user can find information with just 2-3 mouse clicks.
HemoGenix® Announces the Launch of STEMpredict™
1/3/2011. After requests to develop a fast stem cell growth and functionality assay that could be used in stem cell transplantation and cord blood processing laboratories, HemoGenix™ launched STEMpredict™. In contrast to all other assays commercially available, STEMpredict™ is the most rapid and reliable assay to detect stem cell product growth, functionality and viability in a single assay. STEMpredict™ incorporates proven bioluminomics™ technology that allows comparison of results within and between laboratories. Bioluminomics™ technology also allows the assay to be validated, an important aspect for all products that are used in the clinic. For more information on STEMpredict™ applications, click here. To see information on the STEMpredict™ assay, please click here.
Vitro Expands HemoGenix Alliance to Include Cell-based Testing for Liver Toxicity
10/19/2010. HemoGenix® and Vitro Biopharma announced an amendment to jointly manufacture and distribute stem cell analysis tools. Read the Press Release.
Vitro Forms a Strategic Alliance with a Leading Stem Cell Company
4/28/2010. HemoGenix® has forms a strategic alliance with Vitro Biopharma, located in Golden, Colorado to incorporate Vitro's media in its LUMENESC™ Assay Kits for mesenchymal stem cells. Read the Press Release.